Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.57 |
| ▸ | XDH | P47989 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29664708 | 1.00 | CES2 (0.59) | CES2CES1CA1CA2CA12 | |
| SCHEMBL14012582 | 1.00 | CES2 (0.59) | CES2CES1CA1CA2CA12 | |
| SCHEMBL27558516 | 0.88 | ERN1 (0.49) | CES2CES1CA1CA2CA12 | |
| SCHEMBL4652494 | 0.85 | ERN1 (0.64) | CES2CES1CA1CA2CA12 | |
| SCHEMBL2456384 | 0.84 | CA1 (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1401556 | 0.84 | KDM4E (0.58) | CA1CA2CA12CA7CA9 | |
| SCHEMBL851097 | 0.84 | CA1 (0.69) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1495863 | 0.84 | HDAC1 (0.62) | CA1CA2CA12CA7CA9 | |
| SCHEMBL854583 | 0.84 | NOTUM (0.54) | CA1CA2CA12CA7CA9 | |
| SCHEMBL523320 | 0.84 | KDM4E (0.62) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113480993-B | Fluorescent and phosphorescent emission material and preparation method thereof | 华东理工大学 | 2023-03-14 | — | — | CN | claimed |
| CN-115306376-A | Oil-gas well fracturing monitoring reagent, method and application thereof | 中国石油天然气股份有限公司 | 2022-11-08 | — | — | CN | claimed |
| CN-114865080-A | Lithium ion battery electrolyte and lithium ion battery | 香河昆仑新能源材料股份有限公司 | 2022-08-05 | — | — | CN | claimed |
| CN-113480993-A | Fluorescent and phosphorescent emission material and preparation method thereof | 华东理工大学 | 2021-10-08 | — | — | CN | claimed |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4568960-B1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-12577231-B2 | Androgen receptor PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CONTINEUM THERAPEUTICS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| WO-2025262295-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667466-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025224599-A1 | PYRROLIDINE-BASED GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-1647553-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005080360-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| US-6451800-B1 | Phenylpiperazine derivatives as integrin αvβ3 antagonists | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-09-17 | — | — | US | disclosed |
| EP-1227083-A1 | 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2002-07-31 | — | — | EP | disclosed |
| US-6420558-B1 | COMPOUNDS WITH AMIDINE GROUPS ANTAGONISTIC ACTIVITY, CELL ADHESION INHIBITORY ACTIVITY, HUMAN PLATELET AGGREGATION INHIBITORY ACTIVITY, AND THERAPEUTIC AGENTS | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1074543-A1 | AMINOPIPERIDINE DERIVATIVES AS INTEGRIN ALPHA V BETA 3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2001-02-07 | — | — | EP | disclosed |
| EP-1057818-A1 | PHENYLPIPERAZINE DERIVATIVES AS INTEGRIN ALPHAvBETA3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | CES2 1381/4885CES1 1097/4885CA1 1360/4885 |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | AR, CRBN, PSMA3 | CES2 2529/4885CES1 1771/4885CA1 541/4885 |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM3 | CES2 532/4885CES1 314/4885CA1 361/4885 |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM5, CHRM3 | CES2 524/4885CES1 281/4885CA1 477/4885 |
| US-12577231-B2 | Androgen receptor PROTACS | AR, CRBN, PSMA3 | CES2 2529/4885CES1 1771/4885CA1 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.